Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease
- 30 April 2008
- journal article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 168 (2), 181-185
- https://doi.org/10.1007/s00431-008-0727-9
Abstract
Approximately 15–20% of patients with Kawasaki disease (KD) are not responsive to high-dose intravenous gammaglobulin (IVIG). We have previously reported a predictive method for identifying IVIG-non-responsive patients (high-risk KD patients). We determined the safety and effectiveness of pulse methylprednisolone with high-dose IVIG (mPSL+IVIG) as a primary treatment for high-risk KD patients. Sixty-two high-risk KD patients were treated with pulse methylprednisolone 30 mg/kg over 2 h, followed by IVIG 2 g/kg over 24 h (mPSL+IVIG group) and were compared with a historical control group of 32 high-risk patients treated with IVIG 2 g/kg alone at the participating hospitals before this study was opened (IVIG group). High-risk patients were identified with at least two of three predictors (C-reactive protein ≥7 mg/dL, total bilirubin ≥0.9 mg/dL or aspartate aminotransferase ≥200 IU/L). Sixty-six percent (95% confidence interval [CI] 54–78%) of patients had a prompt defervescence in the mPSL+IVIG group compared with 44% (95% CI 26–62%) for the IVIG group (p = 0.048). Coronary artery lesions were observed in 24.2% (95% CI 13.2–35.2%) and 46.9% (95% CI 28.6–65.2%) of patients in the mPSL+IVIG and IVIG groups, respectively (p = 0.025). This is the first report showing that mPSL+IVIG is effective and safe as a primary treatment for high-risk KD patients.Keywords
This publication has 12 references indexed in Scilit:
- Randomized Trial of Pulsed Corticosteroid Therapy for Primary Treatment of Kawasaki DiseaseThe New England Journal of Medicine, 2007
- Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatmentEuropean Journal of Pediatrics, 2006
- Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease: A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart AssociationPEDIATRICS, 2004
- Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki diseaseEuropean Journal of Pediatrics, 2004
- Novel and traditional cardiovascular risk factors in children after Kawasaki disease: Implications for premature atherosclerosisJournal of the American College of Cardiology, 2004
- Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirinThe Journal of Pediatrics, 2000
- Initial Intravenous Gammaglobulin Treatment Failure in Kawasaki DiseasePEDIATRICS, 2000
- Endothelial Dysfunction Late After Kawasaki DiseaseCirculation, 1996
- Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroidsThe Journal of Pediatrics, 1996
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR KAWASAKI DISEASEThe Lancet, 1984